Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.27
NAS:MDSO's Cash to Debt is ranked lower than
69% of the 1923 Companies
in the Global Health Information Services industry.

( Industry Median: 11.11 vs. NAS:MDSO: 1.27 )
Ranked among companies with meaningful Cash to Debt only.
NAS:MDSO' s Cash to Debt Range Over the Past 10 Years
Min: 0.4  Med: 32.34 Max: No Debt
Current: 1.27
Equity to Asset 0.48
NAS:MDSO's Equity to Asset is ranked lower than
67% of the 1811 Companies
in the Global Health Information Services industry.

( Industry Median: 0.62 vs. NAS:MDSO: 0.48 )
Ranked among companies with meaningful Equity to Asset only.
NAS:MDSO' s Equity to Asset Range Over the Past 10 Years
Min: -1.75  Med: 0.42 Max: 0.67
Current: 0.48
-1.75
0.67
Interest Coverage 2.53
NAS:MDSO's Interest Coverage is ranked lower than
92% of the 1628 Companies
in the Global Health Information Services industry.

( Industry Median: 148.64 vs. NAS:MDSO: 2.53 )
Ranked among companies with meaningful Interest Coverage only.
NAS:MDSO' s Interest Coverage Range Over the Past 10 Years
Min: 1.31  Med: 51.54 Max: No Debt
Current: 2.53
F-Score: 6
Z-Score: 6.18
M-Score: -2.52
WACC vs ROIC
12.78%
14.52%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 9.68
NAS:MDSO's Operating margin (%) is ranked higher than
67% of the 1869 Companies
in the Global Health Information Services industry.

( Industry Median: 4.63 vs. NAS:MDSO: 9.68 )
Ranked among companies with meaningful Operating margin (%) only.
NAS:MDSO' s Operating margin (%) Range Over the Past 10 Years
Min: -36.17  Med: 7.45 Max: 14
Current: 9.68
-36.17
14
Net-margin (%) 5.70
NAS:MDSO's Net-margin (%) is ranked higher than
61% of the 1869 Companies
in the Global Health Information Services industry.

( Industry Median: 3.09 vs. NAS:MDSO: 5.70 )
Ranked among companies with meaningful Net-margin (%) only.
NAS:MDSO' s Net-margin (%) Range Over the Past 10 Years
Min: -52.41  Med: 3.52 Max: 21.36
Current: 5.7
-52.41
21.36
ROE (%) 7.93
NAS:MDSO's ROE (%) is ranked higher than
57% of the 1814 Companies
in the Global Health Information Services industry.

( Industry Median: 5.56 vs. NAS:MDSO: 7.93 )
Ranked among companies with meaningful ROE (%) only.
NAS:MDSO' s ROE (%) Range Over the Past 10 Years
Min: 2.48  Med: 11.85 Max: 63.95
Current: 7.93
2.48
63.95
ROA (%) 3.53
NAS:MDSO's ROA (%) is ranked higher than
54% of the 1924 Companies
in the Global Health Information Services industry.

( Industry Median: 2.77 vs. NAS:MDSO: 3.53 )
Ranked among companies with meaningful ROA (%) only.
NAS:MDSO' s ROA (%) Range Over the Past 10 Years
Min: -106.4  Med: 4.18 Max: 22.66
Current: 3.53
-106.4
22.66
ROC (Joel Greenblatt) (%) 84.11
NAS:MDSO's ROC (Joel Greenblatt) (%) is ranked higher than
72% of the 1886 Companies
in the Global Health Information Services industry.

( Industry Median: 21.17 vs. NAS:MDSO: 84.11 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NAS:MDSO' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -318.3  Med: 71.34 Max: 277.92
Current: 84.11
-318.3
277.92
Revenue Growth (3Y)(%) 17.40
NAS:MDSO's Revenue Growth (3Y)(%) is ranked higher than
80% of the 1456 Companies
in the Global Health Information Services industry.

( Industry Median: 5.00 vs. NAS:MDSO: 17.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NAS:MDSO' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -21.7  Med: 8.2 Max: 17.5
Current: 17.4
-21.7
17.5
EBITDA Growth (3Y)(%) 2.20
NAS:MDSO's EBITDA Growth (3Y)(%) is ranked lower than
59% of the 1202 Companies
in the Global Health Information Services industry.

( Industry Median: 7.70 vs. NAS:MDSO: 2.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NAS:MDSO' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -2.3 Max: 14.7
Current: 2.2
0
14.7
EPS Growth (3Y)(%) -13.10
NAS:MDSO's EPS Growth (3Y)(%) is ranked lower than
72% of the 1087 Companies
in the Global Health Information Services industry.

( Industry Median: 6.80 vs. NAS:MDSO: -13.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NAS:MDSO' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -48.4  Med: -13.2 Max: 40.9
Current: -13.1
-48.4
40.9
» NAS:MDSO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q4 2015

MDSO Guru Trades in Q4 2015

Chuck Royce 155,665 sh (unchged)
Jim Simons Sold Out
Ron Baron Sold Out
Frank Sands 5,465,577 sh (-0.63%)
Columbia Wanger 1,861,230 sh (-4.83%)
» More
Q1 2016

MDSO Guru Trades in Q1 2016

Chuck Royce 188,165 sh (+20.88%)
Columbia Wanger 1,864,018 sh (+0.15%)
Frank Sands 4,140,933 sh (-24.24%)
» More
Q2 2016

MDSO Guru Trades in Q2 2016

Joel Greenblatt 8,271 sh (New)
Chuck Royce 188,165 sh (unchged)
Frank Sands 4,002,133 sh (-3.35%)
Columbia Wanger 1,729,046 sh (-7.24%)
» More
Q3 2016

MDSO Guru Trades in Q3 2016

Paul Tudor Jones 6,643 sh (New)
Chuck Royce 188,165 sh (unchged)
Joel Greenblatt Sold Out
Frank Sands 3,862,933 sh (-3.48%)
Columbia Wanger 851,182 sh (-50.77%)
» More
» Details

Insider Trades

Latest Guru Trades with MDSO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Application Software » Health Information Services
Compare:NAS:HQY, NAS:ATHN, NAS:INOV, NAS:WBMD, NAS:NH, NAS:PINC, NYSE:EVH, NAS:OMCL, NAS:QSII, NYSE:TDOC, NAS:HSTM, OTCPK:PMCUF, NYSE:EVDY, NAS:CPSI, OTCPK:ACHI, OTCPK:SNBP, OTCPK:TLLT, OTCPK:CNAB, OTCPK:OMCM, NAS:STRM » details
Traded in other countries:2M9.Germany,
Medidata Solutions Inc provides cloud-based solutions for life sciences. It offers products and services including Medidata Rave, Medidata CTMS, Medidata Designer, Medidata Insights, and Medidata Grants Manager.

Medidata Solutions Inc was incorporated in June 1999and reincorporated in the State of Delaware in May 2000. The Company is a provider of cloud-based solutions for clinical research in life sciences, designed to transform clinical development and increase the value of the customers' research investments. Medidata's solutions are designed to address the underlying requirements of clinical development, rather than just its current processes, to maximize the value of the overall research process. Its cloud-based solutions, metrics and services allow users to accurately and efficiently design clinical trials; manage and monitor ongoing trial activities; develop and administer trial budgets; capture, manage and report clinical trial data; plan and execute randomized subject allocation methodologies; manage and allocate clinical trial supplies; and view, track, and evaluate trial progress through easy-to-use, Internet-enabled platforms. The Company compete with firms such as Oracle, Perceptive Informatics and others offering products and services that compete with one or more of the solutions. It competes on the basis of several factors, including, breadth and depth of solution offerings; platform capabilities, including interoperability; ease of use of solutions and rates of user adoption; solution functionality and flexibility; analytics and benchmarking; speed and performance required to enable customers to access clinical trial data in real-time; product reliability and scalability; infrastructure accessibility and security; regulatory compliance; financial stability; commercial and technology partnerships; depth of expertise and quality of professional services and customer support on a global basis; and sales and marketing capabilities, including the ability to create and communicate operational value. The Company has registered trademarks and service marks in the United States and abroad, and filed applications for the registration of additional trademarks and service marks. The principal trademarks are "Medidata," "Medidata Clinical Cloud," "Medidata Patient Cloud," "Medidata CRO Contractor," "Medidata Designer," "Medidata Grants Manager," "Medidata Rave," "Medidata Balance," "Medidata Coder," and "Medidata Insights." It also holds several domain names, including the domain names "mdsol.com" and "medidatasolutions.com". The use of Company's software products, services and hosted solutions by customers engaged in clinical trials must be done in a manner that is compliant with a complex array of United States federal and state laws and regulations, including regulation by the Food and Drug Administration, as well as regulations and guidance issued by foreign governments and international non-governmental organizations.

Top Ranked Articles about Medidata Solutions Inc

Columbia Wanger's Largest Trades in 3rd Quarter The guru's most significant transactions
Columbia funds are managed by Columbia Management Investment Advisers LLC, and Columbia Acorn funds are managed by Columbia Wanger (Trades, Portfolio) Asset Management LLC, a subsidiary of Columbia Management Investment Advisers, LLC. During the third quarter the guru’s largest trades were the following: Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 118.95
MDSO's P/E(ttm) is ranked lower than
91% of the 1553 Companies
in the Global Health Information Services industry.

( Industry Median: 23.53 vs. MDSO: 118.95 )
Ranked among companies with meaningful P/E(ttm) only.
MDSO' s P/E(ttm) Range Over the Past 10 Years
Min: 11.29  Med: 98.73 Max: 2129.13
Current: 118.95
11.29
2129.13
Forward P/E 43.48
MDSO's Forward P/E is ranked lower than
79% of the 410 Companies
in the Global Health Information Services industry.

( Industry Median: 22.22 vs. MDSO: 43.48 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 118.95
MDSO's PE(NRI) is ranked lower than
90% of the 1278 Companies
in the Global Health Information Services industry.

( Industry Median: 24.38 vs. MDSO: 118.95 )
Ranked among companies with meaningful PE(NRI) only.
MDSO' s PE(NRI) Range Over the Past 10 Years
Min: 11.06  Med: 97.52 Max: 2129.13
Current: 118.95
11.06
2129.13
Price/Owner Earnings (ttm) 1217.20
MDSO's Price/Owner Earnings (ttm) is ranked lower than
99% of the 769 Companies
in the Global Health Information Services industry.

( Industry Median: 24.50 vs. MDSO: 1217.20 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MDSO' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 28.78  Med: 171.08 Max: 10780
Current: 1217.2
28.78
10780
P/B 7.91
MDSO's P/B is ranked lower than
81% of the 2253 Companies
in the Global Health Information Services industry.

( Industry Median: 2.82 vs. MDSO: 7.91 )
Ranked among companies with meaningful P/B only.
MDSO' s P/B Range Over the Past 10 Years
Min: 4.53  Med: 9.71 Max: 29.12
Current: 7.91
4.53
29.12
P/S 6.83
MDSO's P/S is ranked lower than
80% of the 2248 Companies
in the Global Health Information Services industry.

( Industry Median: 2.31 vs. MDSO: 6.83 )
Ranked among companies with meaningful P/S only.
MDSO' s P/S Range Over the Past 10 Years
Min: 1.29  Med: 5.33 Max: 12.47
Current: 6.83
1.29
12.47
PFCF 55.75
MDSO's PFCF is ranked lower than
78% of the 876 Companies
in the Global Health Information Services industry.

( Industry Median: 25.86 vs. MDSO: 55.75 )
Ranked among companies with meaningful PFCF only.
MDSO' s PFCF Range Over the Past 10 Years
Min: 12.98  Med: 46.71 Max: 274.73
Current: 55.75
12.98
274.73
POCF 38.43
MDSO's POCF is ranked lower than
81% of the 1128 Companies
in the Global Health Information Services industry.

( Industry Median: 18.04 vs. MDSO: 38.43 )
Ranked among companies with meaningful POCF only.
MDSO' s POCF Range Over the Past 10 Years
Min: 10.19  Med: 35.57 Max: 136.33
Current: 38.43
10.19
136.33
EV-to-EBIT 63.91
MDSO's EV-to-EBIT is ranked lower than
86% of the 1574 Companies
in the Global Health Information Services industry.

( Industry Median: 16.92 vs. MDSO: 63.91 )
Ranked among companies with meaningful EV-to-EBIT only.
MDSO' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.7  Med: 55 Max: 344.6
Current: 63.91
8.7
344.6
EV-to-EBITDA 49.24
MDSO's EV-to-EBITDA is ranked lower than
84% of the 1710 Companies
in the Global Health Information Services industry.

( Industry Median: 13.02 vs. MDSO: 49.24 )
Ranked among companies with meaningful EV-to-EBITDA only.
MDSO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.8  Med: 34.95 Max: 133.6
Current: 49.24
6.8
133.6
PEG 633.50
MDSO's PEG is ranked lower than
100% of the 562 Companies
in the Global Health Information Services industry.

( Industry Median: 1.95 vs. MDSO: 633.50 )
Ranked among companies with meaningful PEG only.
MDSO' s PEG Range Over the Past 10 Years
Min: 8.16  Med: 29 Max: 633.5
Current: 633.5
8.16
633.5
Current Ratio 3.81
MDSO's Current Ratio is ranked higher than
78% of the 1800 Companies
in the Global Health Information Services industry.

( Industry Median: 1.98 vs. MDSO: 3.81 )
Ranked among companies with meaningful Current Ratio only.
MDSO' s Current Ratio Range Over the Past 10 Years
Min: 0.44  Med: 2.43 Max: 5.35
Current: 3.81
0.44
5.35
Quick Ratio 3.81
MDSO's Quick Ratio is ranked higher than
80% of the 1800 Companies
in the Global Health Information Services industry.

( Industry Median: 1.83 vs. MDSO: 3.81 )
Ranked among companies with meaningful Quick Ratio only.
MDSO' s Quick Ratio Range Over the Past 10 Years
Min: 0.44  Med: 2.43 Max: 5.35
Current: 3.81
0.44
5.35
Days Sales Outstanding 95.79
MDSO's Days Sales Outstanding is ranked lower than
72% of the 1482 Companies
in the Global Health Information Services industry.

( Industry Median: 66.95 vs. MDSO: 95.79 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDSO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.45  Med: 74.59 Max: 95.79
Current: 95.79
45.45
95.79
Days Payable 4.12
MDSO's Days Payable is ranked lower than
94% of the 1319 Companies
in the Global Health Information Services industry.

( Industry Median: 43.61 vs. MDSO: 4.12 )
Ranked among companies with meaningful Days Payable only.
MDSO' s Days Payable Range Over the Past 10 Years
Min: 4.12  Med: 23.99 Max: 54.1
Current: 4.12
4.12
54.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.60
MDSO's 3-Year Average Share Buyback Ratio is ranked lower than
51% of the 1152 Companies
in the Global Health Information Services industry.

( Industry Median: -2.50 vs. MDSO: -2.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MDSO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -55.7  Med: -4.4 Max: -2.6
Current: -2.6
-55.7
-2.6

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 47.15
MDSO's Price/Net Current Asset Value is ranked lower than
94% of the 1614 Companies
in the Global Health Information Services industry.

( Industry Median: 6.82 vs. MDSO: 47.15 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MDSO' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 8.65  Med: 21.05 Max: 4775
Current: 47.15
8.65
4775
Price/Tangible Book 8.77
MDSO's Price/Tangible Book is ranked lower than
70% of the 1904 Companies
in the Global Health Information Services industry.

( Industry Median: 4.36 vs. MDSO: 8.77 )
Ranked among companies with meaningful Price/Tangible Book only.
MDSO' s Price/Tangible Book Range Over the Past 10 Years
Min: 6.33  Med: 10.65 Max: 154.69
Current: 8.77
6.33
154.69
Price/Projected FCF 3.62
MDSO's Price/Projected FCF is ranked lower than
73% of the 1088 Companies
in the Global Health Information Services industry.

( Industry Median: 1.98 vs. MDSO: 3.62 )
Ranked among companies with meaningful Price/Projected FCF only.
MDSO' s Price/Projected FCF Range Over the Past 10 Years
Min: 3.25  Med: 5.45 Max: 9.77
Current: 3.62
3.25
9.77
Price/Median PS Value 1.28
MDSO's Price/Median PS Value is ranked lower than
64% of the 2048 Companies
in the Global Health Information Services industry.

( Industry Median: 1.09 vs. MDSO: 1.28 )
Ranked among companies with meaningful Price/Median PS Value only.
MDSO' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.25  Med: 0.99 Max: 2.2
Current: 1.28
0.25
2.2
Price/Graham Number 6.81
MDSO's Price/Graham Number is ranked lower than
86% of the 1214 Companies
in the Global Health Information Services industry.

( Industry Median: 2.15 vs. MDSO: 6.81 )
Ranked among companies with meaningful Price/Graham Number only.
MDSO' s Price/Graham Number Range Over the Past 10 Years
Min: 1.88  Med: 7.25 Max: 29.72
Current: 6.81
1.88
29.72
Earnings Yield (Greenblatt) (%) 1.66
MDSO's Earnings Yield (Greenblatt) (%) is ranked lower than
55% of the 2440 Companies
in the Global Health Information Services industry.

( Industry Median: 2.61 vs. MDSO: 1.66 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MDSO' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.3  Med: 1.8 Max: 11.5
Current: 1.66
0.3
11.5
Forward Rate of Return (Yacktman) (%) 5.55
MDSO's Forward Rate of Return (Yacktman) (%) is ranked lower than
60% of the 744 Companies
in the Global Health Information Services industry.

( Industry Median: 10.28 vs. MDSO: 5.55 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MDSO' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -3.1  Med: 0.85 Max: 21.2
Current: 5.55
-3.1
21.2

More Statistics

Revenue (TTM) (Mil) $437.8
EPS (TTM) $ 0.44
Beta1.46
Short Percentage of Float7.67%
52-Week Range $30.22 - 57.85
Shares Outstanding (Mil)57.63

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 466 554 641
EPS ($) 0.96 1.22 1.50
EPS w/o NRI ($) 0.96 1.22 1.50
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for MDSO

Headlines

Articles On GuruFocus.com
These Stocks Are More Than You Think Nov 21 2016 
Columbia Wanger's Largest Trades in 3rd Quarter Nov 11 2016 
There’s More In The Clouds At Medidata Than Just The Valuation Jul 21 2015 
Frank Sands Adds to His Position in Medidata Solutions, Inc. Jul 14 2015 
Medidata: SaaS Business Model Leveraging Growth Of The Company Oct 23 2014 
Frank Sands Adds 5 New Stocks Aug 14 2014 
Medidata Solutions: Benefit from Growing Cloud Applications with This Stock May 27 2014 
Medidata Solutions : A SAAS Provider For Your Portfolio Mar 23 2014 
Medidata Solutions Inc. (MDSO) Chairman & CEO Tarek Sherif sells 8,667 Shares Mar 08 2011 
Medidata Solutions Inc. (MDSO) Chairman & CEO Tarek Sherif sells 8,000 Shares Mar 03 2011 

More From Other Websites
Varian (VAR) in Just 100 List from JUST Capital and Forbes Dec 01 2016
TrovaGene Inks Contract with Boreal Genomics, Stock Down Dec 01 2016
Patterson Companies: Q2 Results Dismal, Forex a Concern Dec 01 2016
Evolent Health (EVH) Prices $110M Convertible Senior Notes Nov 30 2016
Cynosure (CYNO) Gets CFDA Approval to Market Icon System Nov 30 2016
Baxter (BAX) Inks Partnership with Americares, Stock Down Nov 30 2016
Is Integrated Device Technology Inc (IDTI) Going to Burn These Hedge Funds? Nov 29 2016
Varian & Komazawa Establish Radiotherapy Education Center Nov 29 2016
TrovaGene (TROV) Precision Cancer Monitoring Data Positive Nov 29 2016
Cerner Hurt by Low System Sales and Intense Competition Nov 28 2016
athenahealth in Boston Globe's List of "Top Places to Work" Nov 25 2016
Cardinal Health to Acquire Lymphoseek Rights for $80 Million Nov 25 2016
Ecolab: Acquisitions Bode Well, Lowered Forecasts a Concern Nov 25 2016
CryoLife (CRY) Hits 52-Week High: What's Driving the Stock? Nov 24 2016
Veeva Systems Hits Buy Point, Outlook Beats On Expanding Portfolio Nov 23 2016
Medidata to Present at Piper Jaffray Healthcare Conference Nov 21 2016
Medidata Initiates eConnect Program for Data Integration Nov 21 2016
Looking for a Growth Stock? Why It is Time to Focus on Medidata Solutions (MDSO) Nov 18 2016
Medidata Introduces eConnect Partner Program Nov 18 2016
Medidata Introduces eConnect Partner Program Nov 18 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)